Nektar Therapeutics Stock News

ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1

Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ: NKTR ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 2 0 0 1M Ago 0 1 0 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Nektar Therapeutics has an average price target of $10.5 with a high of $21.00 and a low of $6.00. Below is a summary of how these 4 analysts rated Nektar Therapeutics over the past 3 months. The greater the number of bullish ratings, the … Full story available on Benzinga.com

Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 L

Nektar Therapeutics (NASDAQ: NKTR ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 2 0 0 1M Ago 0 1 0 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $10.5 versus the current price of Nektar Therapeutics at $4.285, implying upside. Below is a summary of how these 4 analysts rated Nektar Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the … Full story available on Benzinga.com

Clinical-stage biotech Nektar Therapeutics (NKTR) is trading higher on Tuesday after losing over half of its market cap yesterday in reaction to its failure to reach the main goals in…

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared

Tuesday afternoon''s top analyst upgrades and downgrades included Coupa Software, GoodRx, Mosaic and Nektar Therapeutics.

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

Wells Fargo cut the price target on Coupa Software Incorporated (NYSE: LPI) from $190 to $80. Laredo Petroleum shares fell 29.8% to $63.10 in pre-market trading. Credit Suisse raised HollyFrontier

Markets edged higher to start off Tuesday, as West Texas Intermediate crude slid below the $100 mark.